<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984776</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 06-1-036</org_study_id>
    <nct_id>NCT00984776</nct_id>
  </id_info>
  <brief_title>Detection of Coronary Vulnerable Plaque With Contrast-enhanced Magnetic Resonance Imaging</brief_title>
  <acronym>T9M</acronym>
  <official_title>Detection of Vulnerable Plaque With Coronary Vessel Wall MRI: Contrast Enhanced MRI With Gadofosveset MS-325.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <brief_summary>
    <textblock>
      MRI has the ability to visualize the arterial vessel wall. Wall thickening and
      atherosclerotic plaque components can be visualized in the carotid arteries and the aorta.
      Previous studies also demonstrated the ability of MRI to visualize the coronary vessel wall.
      The ultimate goal of coronary vessel wall imaging is to detect vulnerable atherosclerotic
      plaque thereby. This might prevent complications, e.g., chest pain (angina) or myocardial
      infarction.

      The goal of this study was to validate MRI of the coronary vessel wall by comparing it to
      intravascular ultrasound (IVUS), to detect atherosclerotic plaque in the coronary vessel wall
      and to look at the uptake of the albumin-binding contrast agent gadofosveset in
      atherosclerotic plaques. The main hypothesis is that due to the albumin binding
      characteristics, uptake of the contrast agent will take place in the more vulnerable plaques
      compared to less vulnerable plaques. MRI will be compared to X-ray coronary angiography and
      intravascular ultrasound, two techniques currently considered as the standard of reference
      for imaging of the coronary arteries and vessel wall.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of MRI: comparison with IVUS. Can plaque be detected?</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>uptake contrast agent gadofosveset in atherosclerotic plaque in the coronary vessel wall?</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Stable Angina</condition>
  <condition>Unstable Angina</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast enhanced MRI with Gadofosveset</intervention_name>
    <description>0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter</description>
    <other_name>Vasovist</other_name>
    <other_name>MS-325</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scheduled X-ray angiography for known coronary artery disease, valvular disease or
             chest pain with unknown origin

          -  age &gt; 18 yrs and &lt; 90 yrs

          -  Informed consent

        Exclusion Criteria:

          -  arrhythmia

          -  hemodynamic unstable patients

          -  contra-indications for (contrast-enhanced) MRI

          -  age &lt; 18 yrs or &gt; 90 yrs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Leiner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>T. Leiner, M.D., PhD</name_title>
    <organization>Maastricht University Medical Center</organization>
  </responsible_party>
  <keyword>coronary artery</keyword>
  <keyword>MRI</keyword>
  <keyword>vessel wall imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

